Today Aileron Therapeutics, Inc. (ALRN) Stock Reaches All-Time Low

April 24, 2018 - By Hazel Jackson

The stock of Aileron Therapeutics, Inc. (NASDAQ:ALRN) reached all time low today, Apr, 24 and still has $5.09 target or 6.00 % below today’s $5.41 share price. This indicates more downside for the $79.71 million company. This technical setup was reported by If the $5.09 PT is reached, the company will be worth $4.78M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 10.43% or $0.63 during the last trading session, reaching $5.41. About 31,321 shares traded. Aileron Therapeutics, Inc. (NASDAQ:ALRN) has 0.00% since April 24, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Aileron Therapeutics, Inc. (NASDAQ:ALRN) to report earnings on July, 2. After $-0.47 actual EPS reported by Aileron Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 4.26 % negative EPS growth.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The company has market cap of $79.71 million. The companyÂ’s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It currently has negative earnings. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: